References
- Walton, R and Manos, GH: Psychosis related to ephedra-containing herbal supplement use. South Med J 2003; 96(7):718–20.
- Shekelle, PG, Hardy, ML, Morton, SC, Maglione, M, Mojica, WA, Suttorp, MJ, Rhodes, SL, Jungvig, L and Gagne, J: Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: A meta-analysis. Jama 2003; 289(12):1537–45.
- Knight, J: Safety concerns prompt US ban on dietary supplement. Nature 2004; 427(6970):90.
- Nelson, R: FDA issues alert on ephedra supplements in the USA. Lancet 2004; 363(9403):135.
- Weiner BT: Norepinephrine, epinephrine, and the sym-pathomimetic amines. In: Gilman AG, Goodman LS, Gilman A, eds. Goodman and Gilman 's The Pharma-cological Basis of Therapeutics. New York: MacMillan; 1980: 138–175.
- Yui, K, Goto, K, Ikemoto, S, Ishiguro, T, Angrist, B, Duncan, GE, Sheitman, BB, Lieberman, JA, Bracha, SH and Ali, SF: Neurobiological basis of relapse predic-tion in stimulant-induced psychosis and schizophrenia: The role of sensitization. Mol Psychiatry 1999; 4(6): 512–23.
- Verduin, ML and Labbate, LA: Psychosis and delirium following metabolife use. Psychopharmacol Bull 2002; 36(3):42–5.
- Tan, H-Y and Ang, Y-G: First-episode psychosis in the military: A comparative study of prodromal symptoms. Aust N Z J Psychiatry 2001; 35(4):512–519.
- Sternbach, H: The serotonin syndrome. Am J Psychiatry 1991; 148(6):705–13.
- Carbone, JR: The neuroleptic malignant and serotonin syndromes. Emerg Med Clin North Am 2000; 18(2): 317–25.
- Radomski, JW, Dursun, SM, Reveley, MA and Kutcher, SP: An exploratory approach to the serotonin syndrome: An update of clinical phenomenology and revised diagnostic criteria. Med Hypotheses 2000; 55(3):218–24.
- Hamilton, S and Malone, K: Serotonin syndrome dur-ing treatment with paroxetine and risperidone. J Clin Psychopharmacol 2000; 20(1):103–5.
- Reeves, RR, Mack, JE and Beddingfield, JJ: Neuro-toxic syndrome associated with risperidone and fluvox-amine. Ann Pharmacother 2002; 36(3):440–3.
- Karki, SD and Masood, GR: Combination risperidone and SSRI-induced serotonin syndrome. Ann Pharmaco-ther 2003; 37(3):388–91.
- Ulus, IH, Maher, TJ and Wurtman, RJ: Characterization of phentermine and related compounds as monoamine oxidase (MAO) inhibitors. Biochem Phannacol 2000; 59(12):1611–21.
- Dong, J and Blier, P: Modification of norepinephrine and serotonin, but not dopamine, neuron firing by sus-tained bupropion treatment. Psychopharmacology (Berl) 2001; 155(1): 52–7.